Patents by Inventor Francis J. McMahon

Francis J. McMahon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS TO IDENTIFY PATIENTS AT RISK OF DEVELOPING ADVERSE EVENTS DURING TREATMENT WITH ANTIDEPRESSANT MEDICATION
    Publication number: 20110118133
    Abstract: The invention provides a method of screening patients to identify those patients more likely to exhibit an increased risk of treatment-emergent suicidal ideation comprising: (a) obtaining a sample of genetic material from the patients, and (b) assaying the sample for the presence of a genotype in the patients which is associated with an increased risk of treatment-emergent suicidal ideation, wherein the genotype is characterized by a polymorphism in a gene selected from the group consisting of glutamine receptor, ionotropic, kainate 2 (GRIK2); glutamate receptor ionotropic AMPA 3 (GRIA3); and combinations thereof.
    Type: Application
    Filed: January 27, 2011
    Publication date: May 19, 2011
    Applicants: The United States of America, Represented by the Secretary, Department of Health, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Francis J. McMahon, Gonzalo E. Laje, Silvia Paddock, Husseini K. Manji, A. John Rush
  • Methods to identify patients at risk of developing adverse events during treatment with antidepressant medication
    Patent number: 7906283
    Abstract: The invention provides a method of screening patients to identify those patients more likely to exhibit an increased risk of treatment-emergent suicidal ideation comprising: (a) obtaining a sample of genetic material from the patients, and (b) assaying the sample for the presence of a genotype in the patients which is associated with an increased risk of treatment-emergent suicidal ideation, wherein the genotype is characterized by a polymorphism in a gene selected from the group consisting of glutamine receptor, ionotropic, kainate 2 (GRIK2); glutamate receptor ionotropic AMPA 3 (GRIA3); and combinations thereof.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: March 15, 2011
    Assignees: The United States of America as represented by the Department of Health and Human Services, Board of Regents, the University of Texas System
    Inventors: Francis J. McMahon, Gonzalo E. Laje, Silvia Paddock, Husseini K. Manji, A. John Rush
  • Methods to predict the outcome of treatment with antidepressant medication
    Patent number: 7795033
    Abstract: The invention provides a method for determining the outcome of treatment with an antidepressant medication in a patient. In particular, the invention provides a method of screening patients to identify those patients with a decreased risk of non-response to treatment with antidepressant medication by obtaining a sample of genetic material from the patients, and then assaying the sample for the presence of a genotype which is associated with a decreased risk of non-response to treatment with antidepressant medication. The genotype is characterized by a polymorphism in the genes HTR2A, GRIK4, BCL2, and a combination thereof.
    Type: Grant
    Filed: March 19, 2008
    Date of Patent: September 14, 2010
    Assignees: The United States of America as represented by the Department of Health and Human Services, Board of Regents, The University of Texas System
    Inventors: Francis J. McMahon, Gonzalo E. Laje, Silvia Paddock, Husseini K. Manji, A. John Rush, Alexander F. Wilson
  • METHODS TO PREDICT THE OUTCOME OF TREATMENT WITH ANTIDEPRESSANT MEDICATION
    Publication number: 20080233657
    Abstract: The invention provides a method for determining the outcome of treatment with an antidepressant medication in a patient. In particular, the invention provides a method of screening patients to identify those patients with a decreased risk of non-response to treatment with antidepressant medication comprising: (a) obtaining a sample of genetic material from the patients, and (b) assaying the sample for the presence of a genotype in the patients which is associated with a decreased risk of non-response to treatment with antidepressant medication, wherein the genotype is characterized by a polymorphism in a HTR2A, GRIK4, BCL2, or a combination thereof.
    Type: Application
    Filed: March 19, 2008
    Publication date: September 25, 2008
    Applicants: Gov. of the United States of America, represented by the Secretary, Dept. of Health and, Board fo Regents, The University of Texas System
    Inventors: Francis J. McMahon, Gonzalo E. Laje, Silvia Paddock, Husseini K. Manji, Alexander F. Wilson